PADI2 and ovarian carcinoma: The findings presented here suggest a novel therapeutic approach to the Olaparib resistance of ovarian cancer and PADI2 as a prognostic marker in advanced ovarian cancer enhances sensitivity of Olaparib to ovarian cancer.